nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—NFKB1—atherosclerosis	0.347	0.689	CbGaD
Thalidomide—TNF—atherosclerosis	0.106	0.211	CbGaD
Thalidomide—PTGS2—atherosclerosis	0.0506	0.1	CbGaD
Thalidomide—CYP3A5—Rosuvastatin—atherosclerosis	0.0284	0.117	CbGbCtD
Thalidomide—CYP3A5—Simvastatin—atherosclerosis	0.0264	0.109	CbGbCtD
Thalidomide—CYP3A5—Pravastatin—atherosclerosis	0.0258	0.106	CbGbCtD
Thalidomide—CYP3A5—Lovastatin—atherosclerosis	0.0258	0.106	CbGbCtD
Thalidomide—CYP2C19—Rosuvastatin—atherosclerosis	0.0229	0.0943	CbGbCtD
Thalidomide—CYP2C19—Simvastatin—atherosclerosis	0.0213	0.0877	CbGbCtD
Thalidomide—CYP2C19—Lovastatin—atherosclerosis	0.0208	0.0858	CbGbCtD
Thalidomide—CYP2C9—Rosuvastatin—atherosclerosis	0.019	0.0784	CbGbCtD
Thalidomide—CYP2C9—Simvastatin—atherosclerosis	0.0177	0.0729	CbGbCtD
Thalidomide—CYP2C9—Pravastatin—atherosclerosis	0.0173	0.0713	CbGbCtD
Thalidomide—CYP2C9—Lovastatin—atherosclerosis	0.0173	0.0713	CbGbCtD
Thalidomide—Menadione—F7—atherosclerosis	0.00204	0.46	CrCbGaD
Thalidomide—PTGS2—leg—atherosclerosis	0.00114	0.0669	CbGeAlD
Thalidomide—NFKB1—connective tissue—atherosclerosis	0.00109	0.0641	CbGeAlD
Thalidomide—PTGS2—hindlimb—atherosclerosis	0.00102	0.0598	CbGeAlD
Thalidomide—NFKB1—cardiovascular system—atherosclerosis	0.000951	0.0558	CbGeAlD
Thalidomide—PTGS2—appendage—atherosclerosis	0.000874	0.0513	CbGeAlD
Thalidomide—NFKB1—adipose tissue—atherosclerosis	0.000838	0.0492	CbGeAlD
Thalidomide—FGFR2—connective tissue—atherosclerosis	0.000821	0.0481	CbGeAlD
Thalidomide—FGFR2—cardiovascular system—atherosclerosis	0.000714	0.0419	CbGeAlD
Thalidomide—CRBN—adipose tissue—atherosclerosis	0.000703	0.0412	CbGeAlD
Thalidomide—Pomalidomide—TNF—atherosclerosis	0.000687	0.155	CrCbGaD
Thalidomide—PTGS1—artery—atherosclerosis	0.000653	0.0383	CbGeAlD
Thalidomide—FGFR2—adipose tissue—atherosclerosis	0.00063	0.0369	CbGeAlD
Thalidomide—PTGS2—artery—atherosclerosis	0.000624	0.0366	CbGeAlD
Thalidomide—Menadione—F2—atherosclerosis	0.000624	0.141	CrCbGaD
Thalidomide—NFKB1—liver—atherosclerosis	0.000588	0.0345	CbGeAlD
Thalidomide—PTGS1—endothelium—atherosclerosis	0.000552	0.0324	CbGeAlD
Thalidomide—PTGS2—endothelium—atherosclerosis	0.000527	0.0309	CbGeAlD
Thalidomide—PTGS1—blood vessel—atherosclerosis	0.000509	0.0299	CbGeAlD
Thalidomide—CRBN—liver—atherosclerosis	0.000493	0.0289	CbGeAlD
Thalidomide—PTGS2—blood vessel—atherosclerosis	0.000486	0.0285	CbGeAlD
Thalidomide—FGFR2—liver—atherosclerosis	0.000442	0.0259	CbGeAlD
Thalidomide—Menadione—MTHFR—atherosclerosis	0.0004	0.0904	CrCbGaD
Thalidomide—Lenalidomide—PTGS2—atherosclerosis	0.000351	0.0794	CrCbGaD
Thalidomide—Pomalidomide—PTGS2—atherosclerosis	0.000327	0.0738	CrCbGaD
Thalidomide—PTGS1—connective tissue—atherosclerosis	0.000261	0.0153	CbGeAlD
Thalidomide—PTGS2—connective tissue—atherosclerosis	0.000249	0.0146	CbGeAlD
Thalidomide—CYP2C9—cardiovascular system—atherosclerosis	0.000249	0.0146	CbGeAlD
Thalidomide—CYP2E1—cardiovascular system—atherosclerosis	0.000236	0.0138	CbGeAlD
Thalidomide—CYP1A1—adipose tissue—atherosclerosis	0.000228	0.0134	CbGeAlD
Thalidomide—PTGS1—cardiovascular system—atherosclerosis	0.000227	0.0133	CbGeAlD
Thalidomide—CYP3A5—adipose tissue—atherosclerosis	0.000223	0.0131	CbGeAlD
Thalidomide—PTGS2—cardiovascular system—atherosclerosis	0.000217	0.0127	CbGeAlD
Thalidomide—PTGS1—adipose tissue—atherosclerosis	0.0002	0.0117	CbGeAlD
Thalidomide—CYP2C19—liver—atherosclerosis	0.000198	0.0116	CbGeAlD
Thalidomide—PTGS2—adipose tissue—atherosclerosis	0.000191	0.0112	CbGeAlD
Thalidomide—Angioedema—Lovastatin—atherosclerosis	0.000165	0.00139	CcSEcCtD
Thalidomide—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000164	0.00139	CcSEcCtD
Thalidomide—Anaemia—Ezetimibe—atherosclerosis	0.000164	0.00138	CcSEcCtD
Thalidomide—Tinnitus—Pravastatin—atherosclerosis	0.000163	0.00138	CcSEcCtD
Thalidomide—Malaise—Lovastatin—atherosclerosis	0.000163	0.00137	CcSEcCtD
Thalidomide—Cardiac disorder—Pravastatin—atherosclerosis	0.000163	0.00137	CcSEcCtD
Thalidomide—Muscle spasms—Simvastatin—atherosclerosis	0.000162	0.00137	CcSEcCtD
Thalidomide—Vertigo—Lovastatin—atherosclerosis	0.000162	0.00137	CcSEcCtD
Thalidomide—CYP1A2—liver—atherosclerosis	0.000162	0.0095	CbGeAlD
Thalidomide—Angioedema—Ezetimibe—atherosclerosis	0.000162	0.00137	CcSEcCtD
Thalidomide—Angiopathy—Niacin—atherosclerosis	0.000161	0.00136	CcSEcCtD
Thalidomide—Leukopenia—Lovastatin—atherosclerosis	0.000161	0.00136	CcSEcCtD
Thalidomide—CYP1A1—liver—atherosclerosis	0.00016	0.00938	CbGeAlD
Thalidomide—Chills—Niacin—atherosclerosis	0.00016	0.00135	CcSEcCtD
Thalidomide—Malaise—Ezetimibe—atherosclerosis	0.00016	0.00135	CcSEcCtD
Thalidomide—Vision blurred—Simvastatin—atherosclerosis	0.000159	0.00134	CcSEcCtD
Thalidomide—Arrhythmia—Niacin—atherosclerosis	0.000159	0.00134	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000158	0.00134	CcSEcCtD
Thalidomide—Tremor—Simvastatin—atherosclerosis	0.000158	0.00134	CcSEcCtD
Thalidomide—Alopecia—Niacin—atherosclerosis	0.000157	0.00133	CcSEcCtD
Thalidomide—Chills—Pravastatin—atherosclerosis	0.000157	0.00133	CcSEcCtD
Thalidomide—Insomnia—Rosuvastatin—atherosclerosis	0.000157	0.00133	CcSEcCtD
Thalidomide—Ill-defined disorder—Simvastatin—atherosclerosis	0.000157	0.00132	CcSEcCtD
Thalidomide—Arrhythmia—Pravastatin—atherosclerosis	0.000157	0.00132	CcSEcCtD
Thalidomide—Palpitations—Ezetimibe—atherosclerosis	0.000156	0.00132	CcSEcCtD
Thalidomide—CYP3A5—liver—atherosclerosis	0.000156	0.00917	CbGeAlD
Thalidomide—Paraesthesia—Rosuvastatin—atherosclerosis	0.000156	0.00132	CcSEcCtD
Thalidomide—Anaemia—Simvastatin—atherosclerosis	0.000156	0.00132	CcSEcCtD
Thalidomide—Malnutrition—Niacin—atherosclerosis	0.000155	0.00131	CcSEcCtD
Thalidomide—Alopecia—Pravastatin—atherosclerosis	0.000155	0.00131	CcSEcCtD
Thalidomide—Cough—Ezetimibe—atherosclerosis	0.000154	0.0013	CcSEcCtD
Thalidomide—Angioedema—Simvastatin—atherosclerosis	0.000154	0.0013	CcSEcCtD
Thalidomide—CYP2C9—liver—atherosclerosis	0.000154	0.00902	CbGeAlD
Thalidomide—Myalgia—Lovastatin—atherosclerosis	0.000154	0.0013	CcSEcCtD
Thalidomide—Arthralgia—Lovastatin—atherosclerosis	0.000154	0.0013	CcSEcCtD
Thalidomide—Chest pain—Lovastatin—atherosclerosis	0.000154	0.0013	CcSEcCtD
Thalidomide—Anxiety—Lovastatin—atherosclerosis	0.000153	0.00129	CcSEcCtD
Thalidomide—Dyspepsia—Rosuvastatin—atherosclerosis	0.000153	0.00129	CcSEcCtD
Thalidomide—Hypertension—Ezetimibe—atherosclerosis	0.000153	0.00129	CcSEcCtD
Thalidomide—Flatulence—Niacin—atherosclerosis	0.000153	0.00129	CcSEcCtD
Thalidomide—Malaise—Simvastatin—atherosclerosis	0.000152	0.00129	CcSEcCtD
Thalidomide—Tension—Niacin—atherosclerosis	0.000152	0.00128	CcSEcCtD
Thalidomide—Discomfort—Lovastatin—atherosclerosis	0.000152	0.00128	CcSEcCtD
Thalidomide—Vertigo—Simvastatin—atherosclerosis	0.000152	0.00128	CcSEcCtD
Thalidomide—Leukopenia—Simvastatin—atherosclerosis	0.000151	0.00128	CcSEcCtD
Thalidomide—Arthralgia—Ezetimibe—atherosclerosis	0.000151	0.00127	CcSEcCtD
Thalidomide—Chest pain—Ezetimibe—atherosclerosis	0.000151	0.00127	CcSEcCtD
Thalidomide—Myalgia—Ezetimibe—atherosclerosis	0.000151	0.00127	CcSEcCtD
Thalidomide—Nervousness—Niacin—atherosclerosis	0.00015	0.00127	CcSEcCtD
Thalidomide—Flatulence—Pravastatin—atherosclerosis	0.00015	0.00127	CcSEcCtD
Thalidomide—Dry mouth—Lovastatin—atherosclerosis	0.00015	0.00127	CcSEcCtD
Thalidomide—Tension—Pravastatin—atherosclerosis	0.00015	0.00126	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00015	0.00126	CcSEcCtD
Thalidomide—Dysgeusia—Pravastatin—atherosclerosis	0.000149	0.00126	CcSEcCtD
Thalidomide—Muscle spasms—Niacin—atherosclerosis	0.000149	0.00126	CcSEcCtD
Thalidomide—Discomfort—Ezetimibe—atherosclerosis	0.000149	0.00126	CcSEcCtD
Thalidomide—Pain—Rosuvastatin—atherosclerosis	0.000149	0.00125	CcSEcCtD
Thalidomide—Constipation—Rosuvastatin—atherosclerosis	0.000149	0.00125	CcSEcCtD
Thalidomide—Confusional state—Lovastatin—atherosclerosis	0.000148	0.00125	CcSEcCtD
Thalidomide—Nervousness—Pravastatin—atherosclerosis	0.000148	0.00125	CcSEcCtD
Thalidomide—Dry mouth—Ezetimibe—atherosclerosis	0.000147	0.00124	CcSEcCtD
Thalidomide—Muscle spasms—Pravastatin—atherosclerosis	0.000147	0.00124	CcSEcCtD
Thalidomide—Infection—Lovastatin—atherosclerosis	0.000146	0.00124	CcSEcCtD
Thalidomide—Vision blurred—Niacin—atherosclerosis	0.000146	0.00123	CcSEcCtD
Thalidomide—CYP2E1—liver—atherosclerosis	0.000146	0.00855	CbGeAlD
Thalidomide—Confusional state—Ezetimibe—atherosclerosis	0.000146	0.00123	CcSEcCtD
Thalidomide—Thrombocytopenia—Lovastatin—atherosclerosis	0.000144	0.00122	CcSEcCtD
Thalidomide—Vision blurred—Pravastatin—atherosclerosis	0.000144	0.00121	CcSEcCtD
Thalidomide—Myalgia—Simvastatin—atherosclerosis	0.000144	0.00121	CcSEcCtD
Thalidomide—Arthralgia—Simvastatin—atherosclerosis	0.000144	0.00121	CcSEcCtD
Thalidomide—Chest pain—Simvastatin—atherosclerosis	0.000144	0.00121	CcSEcCtD
Thalidomide—Infection—Ezetimibe—atherosclerosis	0.000143	0.00121	CcSEcCtD
Thalidomide—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000143	0.00121	CcSEcCtD
Thalidomide—Anxiety—Simvastatin—atherosclerosis	0.000143	0.00121	CcSEcCtD
Thalidomide—Tremor—Pravastatin—atherosclerosis	0.000143	0.00121	CcSEcCtD
Thalidomide—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000142	0.0012	CcSEcCtD
Thalidomide—Discomfort—Simvastatin—atherosclerosis	0.000142	0.0012	CcSEcCtD
Thalidomide—Nervous system disorder—Ezetimibe—atherosclerosis	0.000142	0.0012	CcSEcCtD
Thalidomide—Angioedema—Niacin—atherosclerosis	0.000142	0.0012	CcSEcCtD
Thalidomide—Ill-defined disorder—Pravastatin—atherosclerosis	0.000142	0.0012	CcSEcCtD
Thalidomide—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000141	0.00119	CcSEcCtD
Thalidomide—Anaemia—Pravastatin—atherosclerosis	0.000141	0.00119	CcSEcCtD
Thalidomide—Anorexia—Lovastatin—atherosclerosis	0.00014	0.00119	CcSEcCtD
Thalidomide—Skin disorder—Ezetimibe—atherosclerosis	0.00014	0.00118	CcSEcCtD
Thalidomide—Angioedema—Pravastatin—atherosclerosis	0.000139	0.00118	CcSEcCtD
Thalidomide—Vertigo—Niacin—atherosclerosis	0.000139	0.00118	CcSEcCtD
Thalidomide—Syncope—Niacin—atherosclerosis	0.000139	0.00117	CcSEcCtD
Thalidomide—Confusional state—Simvastatin—atherosclerosis	0.000139	0.00117	CcSEcCtD
Thalidomide—Leukopenia—Niacin—atherosclerosis	0.000139	0.00117	CcSEcCtD
Thalidomide—Urticaria—Rosuvastatin—atherosclerosis	0.000138	0.00117	CcSEcCtD
Thalidomide—Oedema—Simvastatin—atherosclerosis	0.000138	0.00116	CcSEcCtD
Thalidomide—Malaise—Pravastatin—atherosclerosis	0.000138	0.00116	CcSEcCtD
Thalidomide—Abdominal pain—Rosuvastatin—atherosclerosis	0.000137	0.00116	CcSEcCtD
Thalidomide—Vertigo—Pravastatin—atherosclerosis	0.000137	0.00116	CcSEcCtD
Thalidomide—Palpitations—Niacin—atherosclerosis	0.000137	0.00116	CcSEcCtD
Thalidomide—Infection—Simvastatin—atherosclerosis	0.000137	0.00116	CcSEcCtD
Thalidomide—Leukopenia—Pravastatin—atherosclerosis	0.000137	0.00115	CcSEcCtD
Thalidomide—Loss of consciousness—Niacin—atherosclerosis	0.000136	0.00115	CcSEcCtD
Thalidomide—Cough—Niacin—atherosclerosis	0.000135	0.00114	CcSEcCtD
Thalidomide—Thrombocytopenia—Simvastatin—atherosclerosis	0.000135	0.00114	CcSEcCtD
Thalidomide—PTGS2—liver—atherosclerosis	0.000134	0.00787	CbGeAlD
Thalidomide—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000134	0.00113	CcSEcCtD
Thalidomide—Insomnia—Lovastatin—atherosclerosis	0.000133	0.00112	CcSEcCtD
Thalidomide—Cough—Pravastatin—atherosclerosis	0.000133	0.00112	CcSEcCtD
Thalidomide—Paraesthesia—Lovastatin—atherosclerosis	0.000132	0.00112	CcSEcCtD
Thalidomide—Arthralgia—Niacin—atherosclerosis	0.000132	0.00111	CcSEcCtD
Thalidomide—Myalgia—Niacin—atherosclerosis	0.000132	0.00111	CcSEcCtD
Thalidomide—Hypertension—Pravastatin—atherosclerosis	0.000132	0.00111	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000132	0.00111	CcSEcCtD
Thalidomide—Anorexia—Simvastatin—atherosclerosis	0.000131	0.00111	CcSEcCtD
Thalidomide—Dyspnoea—Lovastatin—atherosclerosis	0.000131	0.00111	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000131	0.00111	CcSEcCtD
Thalidomide—Insomnia—Ezetimibe—atherosclerosis	0.000131	0.0011	CcSEcCtD
Thalidomide—Chest pain—Pravastatin—atherosclerosis	0.00013	0.0011	CcSEcCtD
Thalidomide—Arthralgia—Pravastatin—atherosclerosis	0.00013	0.0011	CcSEcCtD
Thalidomide—Myalgia—Pravastatin—atherosclerosis	0.00013	0.0011	CcSEcCtD
Thalidomide—Paraesthesia—Ezetimibe—atherosclerosis	0.00013	0.0011	CcSEcCtD
Thalidomide—Dyspepsia—Lovastatin—atherosclerosis	0.00013	0.00109	CcSEcCtD
Thalidomide—Anxiety—Pravastatin—atherosclerosis	0.000129	0.00109	CcSEcCtD
Thalidomide—Dry mouth—Niacin—atherosclerosis	0.000129	0.00109	CcSEcCtD
Thalidomide—Dyspnoea—Ezetimibe—atherosclerosis	0.000129	0.00109	CcSEcCtD
Thalidomide—Discomfort—Pravastatin—atherosclerosis	0.000128	0.00108	CcSEcCtD
Thalidomide—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000128	0.00108	CcSEcCtD
Thalidomide—Decreased appetite—Lovastatin—atherosclerosis	0.000128	0.00108	CcSEcCtD
Thalidomide—Dyspepsia—Ezetimibe—atherosclerosis	0.000127	0.00107	CcSEcCtD
Thalidomide—Fatigue—Lovastatin—atherosclerosis	0.000127	0.00107	CcSEcCtD
Thalidomide—Oedema—Niacin—atherosclerosis	0.000126	0.00107	CcSEcCtD
Thalidomide—Pain—Lovastatin—atherosclerosis	0.000126	0.00106	CcSEcCtD
Thalidomide—Constipation—Lovastatin—atherosclerosis	0.000126	0.00106	CcSEcCtD
Thalidomide—Confusional state—Pravastatin—atherosclerosis	0.000126	0.00106	CcSEcCtD
Thalidomide—Decreased appetite—Ezetimibe—atherosclerosis	0.000126	0.00106	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000125	0.00106	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000125	0.00105	CcSEcCtD
Thalidomide—Asthenia—Rosuvastatin—atherosclerosis	0.000125	0.00105	CcSEcCtD
Thalidomide—Insomnia—Simvastatin—atherosclerosis	0.000125	0.00105	CcSEcCtD
Thalidomide—Oedema—Pravastatin—atherosclerosis	0.000124	0.00105	CcSEcCtD
Thalidomide—Fatigue—Ezetimibe—atherosclerosis	0.000124	0.00105	CcSEcCtD
Thalidomide—Shock—Niacin—atherosclerosis	0.000124	0.00105	CcSEcCtD
Thalidomide—Infection—Pravastatin—atherosclerosis	0.000124	0.00104	CcSEcCtD
Thalidomide—Paraesthesia—Simvastatin—atherosclerosis	0.000124	0.00104	CcSEcCtD
Thalidomide—Constipation—Ezetimibe—atherosclerosis	0.000123	0.00104	CcSEcCtD
Thalidomide—Pain—Ezetimibe—atherosclerosis	0.000123	0.00104	CcSEcCtD
Thalidomide—Tachycardia—Niacin—atherosclerosis	0.000123	0.00104	CcSEcCtD
Thalidomide—Pruritus—Rosuvastatin—atherosclerosis	0.000123	0.00104	CcSEcCtD
Thalidomide—Skin disorder—Niacin—atherosclerosis	0.000123	0.00104	CcSEcCtD
Thalidomide—Dyspnoea—Simvastatin—atherosclerosis	0.000123	0.00104	CcSEcCtD
Thalidomide—Hyperhidrosis—Niacin—atherosclerosis	0.000122	0.00103	CcSEcCtD
Thalidomide—Thrombocytopenia—Pravastatin—atherosclerosis	0.000122	0.00103	CcSEcCtD
Thalidomide—Feeling abnormal—Lovastatin—atherosclerosis	0.000121	0.00102	CcSEcCtD
Thalidomide—Dyspepsia—Simvastatin—atherosclerosis	0.000121	0.00102	CcSEcCtD
Thalidomide—Anorexia—Niacin—atherosclerosis	0.000121	0.00102	CcSEcCtD
Thalidomide—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00012	0.00102	CcSEcCtD
Thalidomide—Hyperhidrosis—Pravastatin—atherosclerosis	0.00012	0.00102	CcSEcCtD
Thalidomide—Decreased appetite—Simvastatin—atherosclerosis	0.00012	0.00101	CcSEcCtD
Thalidomide—Feeling abnormal—Ezetimibe—atherosclerosis	0.000119	0.00101	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000119	0.001	CcSEcCtD
Thalidomide—Diarrhoea—Rosuvastatin—atherosclerosis	0.000119	0.001	CcSEcCtD
Thalidomide—Fatigue—Simvastatin—atherosclerosis	0.000119	0.001	CcSEcCtD
Thalidomide—Anorexia—Pravastatin—atherosclerosis	0.000119	0.001	CcSEcCtD
Thalidomide—Hypotension—Niacin—atherosclerosis	0.000118	0.000998	CcSEcCtD
Thalidomide—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000118	0.000997	CcSEcCtD
Thalidomide—Pain—Simvastatin—atherosclerosis	0.000118	0.000995	CcSEcCtD
Thalidomide—Constipation—Simvastatin—atherosclerosis	0.000118	0.000995	CcSEcCtD
Thalidomide—Urticaria—Lovastatin—atherosclerosis	0.000117	0.000988	CcSEcCtD
Thalidomide—Abdominal pain—Lovastatin—atherosclerosis	0.000116	0.000983	CcSEcCtD
Thalidomide—Body temperature increased—Lovastatin—atherosclerosis	0.000116	0.000983	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000115	0.000973	CcSEcCtD
Thalidomide—Dizziness—Rosuvastatin—atherosclerosis	0.000115	0.00097	CcSEcCtD
Thalidomide—Urticaria—Ezetimibe—atherosclerosis	0.000115	0.000969	CcSEcCtD
Thalidomide—Insomnia—Niacin—atherosclerosis	0.000114	0.000966	CcSEcCtD
Thalidomide—Body temperature increased—Ezetimibe—atherosclerosis	0.000114	0.000964	CcSEcCtD
Thalidomide—Abdominal pain—Ezetimibe—atherosclerosis	0.000114	0.000964	CcSEcCtD
Thalidomide—Paraesthesia—Niacin—atherosclerosis	0.000114	0.000959	CcSEcCtD
Thalidomide—Feeling abnormal—Simvastatin—atherosclerosis	0.000113	0.000959	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000113	0.000958	CcSEcCtD
Thalidomide—Dyspnoea—Niacin—atherosclerosis	0.000113	0.000952	CcSEcCtD
Thalidomide—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000113	0.000951	CcSEcCtD
Thalidomide—Insomnia—Pravastatin—atherosclerosis	0.000113	0.000951	CcSEcCtD
Thalidomide—Somnolence—Niacin—atherosclerosis	0.000112	0.00095	CcSEcCtD
Thalidomide—Paraesthesia—Pravastatin—atherosclerosis	0.000112	0.000944	CcSEcCtD
Thalidomide—Dyspepsia—Niacin—atherosclerosis	0.000111	0.00094	CcSEcCtD
Thalidomide—Dyspnoea—Pravastatin—atherosclerosis	0.000111	0.000938	CcSEcCtD
Thalidomide—Decreased appetite—Niacin—atherosclerosis	0.00011	0.000928	CcSEcCtD
Thalidomide—Dyspepsia—Pravastatin—atherosclerosis	0.00011	0.000926	CcSEcCtD
Thalidomide—Rash—Rosuvastatin—atherosclerosis	0.00011	0.000925	CcSEcCtD
Thalidomide—Dermatitis—Rosuvastatin—atherosclerosis	0.000109	0.000924	CcSEcCtD
Thalidomide—Urticaria—Simvastatin—atherosclerosis	0.000109	0.000924	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Niacin—atherosclerosis	0.000109	0.000922	CcSEcCtD
Thalidomide—Abdominal pain—Simvastatin—atherosclerosis	0.000109	0.00092	CcSEcCtD
Thalidomide—Body temperature increased—Simvastatin—atherosclerosis	0.000109	0.00092	CcSEcCtD
Thalidomide—Headache—Rosuvastatin—atherosclerosis	0.000109	0.000919	CcSEcCtD
Thalidomide—Hypersensitivity—Lovastatin—atherosclerosis	0.000108	0.000916	CcSEcCtD
Thalidomide—Decreased appetite—Pravastatin—atherosclerosis	0.000108	0.000914	CcSEcCtD
Thalidomide—Pain—Niacin—atherosclerosis	0.000108	0.000913	CcSEcCtD
Thalidomide—Fatigue—Pravastatin—atherosclerosis	0.000107	0.000907	CcSEcCtD
Thalidomide—Pain—Pravastatin—atherosclerosis	0.000106	0.000899	CcSEcCtD
Thalidomide—Constipation—Pravastatin—atherosclerosis	0.000106	0.000899	CcSEcCtD
Thalidomide—Hypersensitivity—Ezetimibe—atherosclerosis	0.000106	0.000899	CcSEcCtD
Thalidomide—Asthenia—Lovastatin—atherosclerosis	0.000106	0.000892	CcSEcCtD
Thalidomide—Pruritus—Lovastatin—atherosclerosis	0.000104	0.00088	CcSEcCtD
Thalidomide—Asthenia—Ezetimibe—atherosclerosis	0.000104	0.000875	CcSEcCtD
Thalidomide—Gastrointestinal pain—Niacin—atherosclerosis	0.000103	0.000873	CcSEcCtD
Thalidomide—Nausea—Rosuvastatin—atherosclerosis	0.000103	0.000872	CcSEcCtD
Thalidomide—Feeling abnormal—Pravastatin—atherosclerosis	0.000103	0.000867	CcSEcCtD
Thalidomide—Pruritus—Ezetimibe—atherosclerosis	0.000102	0.000863	CcSEcCtD
Thalidomide—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000102	0.00086	CcSEcCtD
Thalidomide—Hypersensitivity—Simvastatin—atherosclerosis	0.000101	0.000857	CcSEcCtD
Thalidomide—Diarrhoea—Lovastatin—atherosclerosis	0.000101	0.000851	CcSEcCtD
Thalidomide—Urticaria—Niacin—atherosclerosis	0.0001	0.000848	CcSEcCtD
Thalidomide—Body temperature increased—Niacin—atherosclerosis	0.0001	0.000844	CcSEcCtD
Thalidomide—Abdominal pain—Niacin—atherosclerosis	0.0001	0.000844	CcSEcCtD
Thalidomide—Urticaria—Pravastatin—atherosclerosis	9.89e-05	0.000835	CcSEcCtD
Thalidomide—Asthenia—Simvastatin—atherosclerosis	9.88e-05	0.000835	CcSEcCtD
Thalidomide—Diarrhoea—Ezetimibe—atherosclerosis	9.88e-05	0.000835	CcSEcCtD
Thalidomide—Abdominal pain—Pravastatin—atherosclerosis	9.84e-05	0.000831	CcSEcCtD
Thalidomide—Body temperature increased—Pravastatin—atherosclerosis	9.84e-05	0.000831	CcSEcCtD
Thalidomide—Pruritus—Simvastatin—atherosclerosis	9.74e-05	0.000823	CcSEcCtD
Thalidomide—Dizziness—Lovastatin—atherosclerosis	9.74e-05	0.000822	CcSEcCtD
Thalidomide—Dizziness—Ezetimibe—atherosclerosis	9.55e-05	0.000807	CcSEcCtD
Thalidomide—Diarrhoea—Simvastatin—atherosclerosis	9.42e-05	0.000796	CcSEcCtD
Thalidomide—Vomiting—Lovastatin—atherosclerosis	9.36e-05	0.000791	CcSEcCtD
Thalidomide—Hypersensitivity—Niacin—atherosclerosis	9.32e-05	0.000787	CcSEcCtD
Thalidomide—Rash—Lovastatin—atherosclerosis	9.28e-05	0.000784	CcSEcCtD
Thalidomide—Dermatitis—Lovastatin—atherosclerosis	9.27e-05	0.000783	CcSEcCtD
Thalidomide—Headache—Lovastatin—atherosclerosis	9.22e-05	0.000779	CcSEcCtD
Thalidomide—Vomiting—Ezetimibe—atherosclerosis	9.18e-05	0.000776	CcSEcCtD
Thalidomide—Hypersensitivity—Pravastatin—atherosclerosis	9.17e-05	0.000775	CcSEcCtD
Thalidomide—Dizziness—Simvastatin—atherosclerosis	9.11e-05	0.000769	CcSEcCtD
Thalidomide—Rash—Ezetimibe—atherosclerosis	9.1e-05	0.000769	CcSEcCtD
Thalidomide—Dermatitis—Ezetimibe—atherosclerosis	9.1e-05	0.000768	CcSEcCtD
Thalidomide—Asthenia—Niacin—atherosclerosis	9.07e-05	0.000766	CcSEcCtD
Thalidomide—Headache—Ezetimibe—atherosclerosis	9.05e-05	0.000764	CcSEcCtD
Thalidomide—Pruritus—Niacin—atherosclerosis	8.95e-05	0.000756	CcSEcCtD
Thalidomide—Asthenia—Pravastatin—atherosclerosis	8.93e-05	0.000755	CcSEcCtD
Thalidomide—Pruritus—Pravastatin—atherosclerosis	8.81e-05	0.000744	CcSEcCtD
Thalidomide—Vomiting—Simvastatin—atherosclerosis	8.76e-05	0.00074	CcSEcCtD
Thalidomide—Nausea—Lovastatin—atherosclerosis	8.74e-05	0.000739	CcSEcCtD
Thalidomide—Rash—Simvastatin—atherosclerosis	8.68e-05	0.000733	CcSEcCtD
Thalidomide—Dermatitis—Simvastatin—atherosclerosis	8.67e-05	0.000733	CcSEcCtD
Thalidomide—Diarrhoea—Niacin—atherosclerosis	8.65e-05	0.000731	CcSEcCtD
Thalidomide—Headache—Simvastatin—atherosclerosis	8.63e-05	0.000729	CcSEcCtD
Thalidomide—Nausea—Ezetimibe—atherosclerosis	8.58e-05	0.000725	CcSEcCtD
Thalidomide—Diarrhoea—Pravastatin—atherosclerosis	8.52e-05	0.00072	CcSEcCtD
Thalidomide—Dizziness—Niacin—atherosclerosis	8.36e-05	0.000706	CcSEcCtD
Thalidomide—Dizziness—Pravastatin—atherosclerosis	8.23e-05	0.000695	CcSEcCtD
Thalidomide—Nausea—Simvastatin—atherosclerosis	8.18e-05	0.000691	CcSEcCtD
Thalidomide—Vomiting—Niacin—atherosclerosis	8.04e-05	0.000679	CcSEcCtD
Thalidomide—Rash—Niacin—atherosclerosis	7.97e-05	0.000673	CcSEcCtD
Thalidomide—Dermatitis—Niacin—atherosclerosis	7.97e-05	0.000673	CcSEcCtD
Thalidomide—Headache—Niacin—atherosclerosis	7.92e-05	0.000669	CcSEcCtD
Thalidomide—Vomiting—Pravastatin—atherosclerosis	7.92e-05	0.000669	CcSEcCtD
Thalidomide—Rash—Pravastatin—atherosclerosis	7.85e-05	0.000663	CcSEcCtD
Thalidomide—Dermatitis—Pravastatin—atherosclerosis	7.84e-05	0.000662	CcSEcCtD
Thalidomide—Headache—Pravastatin—atherosclerosis	7.8e-05	0.000659	CcSEcCtD
Thalidomide—Nausea—Niacin—atherosclerosis	7.51e-05	0.000634	CcSEcCtD
Thalidomide—Nausea—Pravastatin—atherosclerosis	7.4e-05	0.000625	CcSEcCtD
Thalidomide—FGFR2—Signaling Pathways—INS—atherosclerosis	4.35e-06	3.86e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ABCA1—atherosclerosis	4.33e-06	3.84e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NAMPT—atherosclerosis	4.32e-06	3.83e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ABCA1—atherosclerosis	4.32e-06	3.83e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CD36—atherosclerosis	4.32e-06	3.83e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—LPL—atherosclerosis	4.31e-06	3.82e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	4.3e-06	3.81e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—LIPC—atherosclerosis	4.29e-06	3.81e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCL2—atherosclerosis	4.28e-06	3.8e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOC3—atherosclerosis	4.27e-06	3.79e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—LDLR—atherosclerosis	4.24e-06	3.76e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MAPK3—atherosclerosis	4.24e-06	3.76e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—AKT1—atherosclerosis	4.23e-06	3.76e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LPA—atherosclerosis	4.21e-06	3.74e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SERPINE1—atherosclerosis	4.21e-06	3.74e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—STAT3—atherosclerosis	4.21e-06	3.74e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IGF1—atherosclerosis	4.21e-06	3.73e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PRKCG—atherosclerosis	4.19e-06	3.72e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CETP—atherosclerosis	4.14e-06	3.68e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	4.13e-06	3.66e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MTHFR—atherosclerosis	4.09e-06	3.63e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ABCA1—atherosclerosis	4.08e-06	3.62e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—BGN—atherosclerosis	4.08e-06	3.62e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	4.06e-06	3.6e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	4.05e-06	3.59e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOA5—atherosclerosis	4.04e-06	3.58e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MAPK3—atherosclerosis	4.02e-06	3.57e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOS3—atherosclerosis	4.02e-06	3.57e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARA—atherosclerosis	4.02e-06	3.56e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SERPINE1—atherosclerosis	4e-06	3.55e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SCARB1—atherosclerosis	3.97e-06	3.52e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—HMOX1—atherosclerosis	3.95e-06	3.5e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NAMPT—atherosclerosis	3.94e-06	3.5e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	3.92e-06	3.48e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	3.92e-06	3.48e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—LIPC—atherosclerosis	3.92e-06	3.47e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOC3—atherosclerosis	3.89e-06	3.45e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AGT—atherosclerosis	3.89e-06	3.45e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PLA2G1B—atherosclerosis	3.89e-06	3.45e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—STAT3—atherosclerosis	3.89e-06	3.45e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MTHFR—atherosclerosis	3.88e-06	3.44e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—LDLR—atherosclerosis	3.87e-06	3.43e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	3.86e-06	3.43e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	3.84e-06	3.41e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOS3—atherosclerosis	3.82e-06	3.39e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOE—atherosclerosis	3.81e-06	3.38e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	3.81e-06	3.38e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	3.8e-06	3.37e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOB—atherosclerosis	3.78e-06	3.35e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CETP—atherosclerosis	3.78e-06	3.35e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PDGFB—atherosclerosis	3.78e-06	3.35e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CAV1—atherosclerosis	3.78e-06	3.35e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOA1—atherosclerosis	3.77e-06	3.34e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALOX5—atherosclerosis	3.75e-06	3.33e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HMGCR—atherosclerosis	3.75e-06	3.32e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—HMOX1—atherosclerosis	3.71e-06	3.3e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MAPK3—atherosclerosis	3.71e-06	3.29e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—HMOX1—atherosclerosis	3.71e-06	3.29e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTM1—atherosclerosis	3.68e-06	3.26e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SCARB1—atherosclerosis	3.62e-06	3.21e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOE—atherosclerosis	3.61e-06	3.2e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—LPL—atherosclerosis	3.61e-06	3.2e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFB1—atherosclerosis	3.6e-06	3.2e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CAV1—atherosclerosis	3.58e-06	3.17e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOA1—atherosclerosis	3.57e-06	3.17e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL8—atherosclerosis	3.57e-06	3.16e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOB—atherosclerosis	3.56e-06	3.16e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOB—atherosclerosis	3.55e-06	3.15e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	3.52e-06	3.13e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GPX1—atherosclerosis	3.52e-06	3.12e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—HMOX1—atherosclerosis	3.5e-06	3.11e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	3.47e-06	3.08e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTM1—atherosclerosis	3.46e-06	3.07e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTM1—atherosclerosis	3.45e-06	3.06e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CG—atherosclerosis	3.44e-06	3.05e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CD36—atherosclerosis	3.43e-06	3.04e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HMGCR—atherosclerosis	3.42e-06	3.03e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—LPL—atherosclerosis	3.4e-06	3.01e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—LPL—atherosclerosis	3.39e-06	3.01e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL8—atherosclerosis	3.38e-06	3e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	3.38e-06	3e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NAMPT—atherosclerosis	3.37e-06	2.99e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS2—atherosclerosis	3.37e-06	2.99e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOB—atherosclerosis	3.35e-06	2.98e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	3.35e-06	2.97e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LIPC—atherosclerosis	3.35e-06	2.97e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ABCA1—atherosclerosis	3.34e-06	2.96e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOC3—atherosclerosis	3.33e-06	2.95e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARG—atherosclerosis	3.32e-06	2.94e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GPX1—atherosclerosis	3.31e-06	2.94e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GPX1—atherosclerosis	3.31e-06	2.93e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LDLR—atherosclerosis	3.31e-06	2.93e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTM1—atherosclerosis	3.26e-06	2.89e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—INS—atherosclerosis	3.26e-06	2.89e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MTHFR—atherosclerosis	3.25e-06	2.88e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CETP—atherosclerosis	3.23e-06	2.86e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CD36—atherosclerosis	3.23e-06	2.86e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—atherosclerosis	3.23e-06	2.86e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CD36—atherosclerosis	3.22e-06	2.86e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—LPL—atherosclerosis	3.2e-06	2.84e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARA—atherosclerosis	3.19e-06	2.83e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK8—atherosclerosis	3.14e-06	2.78e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GPX1—atherosclerosis	3.12e-06	2.77e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—atherosclerosis	3.1e-06	2.75e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SCARB1—atherosclerosis	3.09e-06	2.74e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AGT—atherosclerosis	3.09e-06	2.74e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—INS—atherosclerosis	3.09e-06	2.74e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	3.08e-06	2.73e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—atherosclerosis	3.06e-06	2.72e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MTHFR—atherosclerosis	3.06e-06	2.71e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MTHFR—atherosclerosis	3.05e-06	2.71e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ABCA1—atherosclerosis	3.05e-06	2.7e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CD36—atherosclerosis	3.04e-06	2.7e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NFKB1—atherosclerosis	3.03e-06	2.69e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOE—atherosclerosis	3.02e-06	2.68e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	3.01e-06	2.67e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARA—atherosclerosis	3e-06	2.66e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CAV1—atherosclerosis	3e-06	2.66e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARA—atherosclerosis	2.99e-06	2.66e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOA1—atherosclerosis	2.99e-06	2.65e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—atherosclerosis	2.98e-06	2.65e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK8—atherosclerosis	2.98e-06	2.64e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—atherosclerosis	2.94e-06	2.61e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HMGCR—atherosclerosis	2.92e-06	2.59e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AGT—atherosclerosis	2.91e-06	2.58e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AGT—atherosclerosis	2.9e-06	2.57e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—atherosclerosis	2.9e-06	2.57e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MTHFR—atherosclerosis	2.88e-06	2.56e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—STAT3—atherosclerosis	2.87e-06	2.55e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HMOX1—atherosclerosis	2.87e-06	2.54e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—atherosclerosis	2.86e-06	2.54e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NOS3—atherosclerosis	2.85e-06	2.53e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOE—atherosclerosis	2.85e-06	2.53e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOE—atherosclerosis	2.84e-06	2.52e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SERPINE1—atherosclerosis	2.83e-06	2.51e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARA—atherosclerosis	2.83e-06	2.51e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CAV1—atherosclerosis	2.82e-06	2.5e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CAV1—atherosclerosis	2.82e-06	2.5e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOA1—atherosclerosis	2.81e-06	2.5e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOA1—atherosclerosis	2.81e-06	2.49e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—atherosclerosis	2.75e-06	2.44e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOB—atherosclerosis	2.74e-06	2.44e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK3—atherosclerosis	2.74e-06	2.43e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AGT—atherosclerosis	2.74e-06	2.43e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CG—atherosclerosis	2.73e-06	2.42e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—STAT3—atherosclerosis	2.72e-06	2.41e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—atherosclerosis	2.71e-06	2.41e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—atherosclerosis	2.71e-06	2.41e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS3—atherosclerosis	2.71e-06	2.4e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOE—atherosclerosis	2.68e-06	2.38e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTM1—atherosclerosis	2.67e-06	2.37e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CAV1—atherosclerosis	2.66e-06	2.36e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—atherosclerosis	2.66e-06	2.36e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOA1—atherosclerosis	2.65e-06	2.35e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARG—atherosclerosis	2.63e-06	2.34e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	2.63e-06	2.34e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—LPL—atherosclerosis	2.62e-06	2.33e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HMOX1—atherosclerosis	2.61e-06	2.32e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—atherosclerosis	2.61e-06	2.32e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ABCA1—atherosclerosis	2.6e-06	2.31e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK3—atherosclerosis	2.6e-06	2.31e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—INS—atherosclerosis	2.58e-06	2.29e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CG—atherosclerosis	2.57e-06	2.28e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CG—atherosclerosis	2.56e-06	2.28e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GPX1—atherosclerosis	2.56e-06	2.27e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—atherosclerosis	2.52e-06	2.24e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—atherosclerosis	2.5e-06	2.22e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOB—atherosclerosis	2.5e-06	2.22e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CD36—atherosclerosis	2.49e-06	2.21e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARG—atherosclerosis	2.48e-06	2.2e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARG—atherosclerosis	2.48e-06	2.2e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTM1—atherosclerosis	2.43e-06	2.16e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—INS—atherosclerosis	2.43e-06	2.16e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—INS—atherosclerosis	2.43e-06	2.15e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CG—atherosclerosis	2.42e-06	2.15e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—LPL—atherosclerosis	2.39e-06	2.12e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—atherosclerosis	2.37e-06	2.1e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MTHFR—atherosclerosis	2.36e-06	2.09e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARG—atherosclerosis	2.34e-06	2.07e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GPX1—atherosclerosis	2.33e-06	2.07e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARA—atherosclerosis	2.32e-06	2.05e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—INS—atherosclerosis	2.29e-06	2.03e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CD36—atherosclerosis	2.27e-06	2.01e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NOS3—atherosclerosis	2.27e-06	2.01e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AGT—atherosclerosis	2.24e-06	1.99e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HMOX1—atherosclerosis	2.23e-06	1.98e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—atherosclerosis	2.23e-06	1.98e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—atherosclerosis	2.23e-06	1.97e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOE—atherosclerosis	2.2e-06	1.95e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CAV1—atherosclerosis	2.18e-06	1.93e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOA1—atherosclerosis	2.17e-06	1.93e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MTHFR—atherosclerosis	2.15e-06	1.91e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOB—atherosclerosis	2.14e-06	1.9e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NOS3—atherosclerosis	2.13e-06	1.89e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NOS3—atherosclerosis	2.13e-06	1.89e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARA—atherosclerosis	2.11e-06	1.87e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—atherosclerosis	2.1e-06	1.87e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTM1—atherosclerosis	2.08e-06	1.85e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AGT—atherosclerosis	2.04e-06	1.81e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LPL—atherosclerosis	2.04e-06	1.81e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NOS3—atherosclerosis	2.01e-06	1.78e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—atherosclerosis	2e-06	1.78e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOE—atherosclerosis	2e-06	1.78e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GPX1—atherosclerosis	1.99e-06	1.77e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CAV1—atherosclerosis	1.98e-06	1.76e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CG—atherosclerosis	1.98e-06	1.76e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOA1—atherosclerosis	1.98e-06	1.76e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—atherosclerosis	1.95e-06	1.73e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—atherosclerosis	1.95e-06	1.73e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CD36—atherosclerosis	1.94e-06	1.72e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—STAT3—atherosclerosis	1.93e-06	1.71e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARG—atherosclerosis	1.91e-06	1.7e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—atherosclerosis	1.9e-06	1.69e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—INS—atherosclerosis	1.88e-06	1.67e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT1—atherosclerosis	1.85e-06	1.64e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAPK3—atherosclerosis	1.84e-06	1.64e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—atherosclerosis	1.84e-06	1.63e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTHFR—atherosclerosis	1.84e-06	1.63e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CG—atherosclerosis	1.81e-06	1.6e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARA—atherosclerosis	1.8e-06	1.6e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—atherosclerosis	1.79e-06	1.59e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—atherosclerosis	1.75e-06	1.56e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AGT—atherosclerosis	1.75e-06	1.55e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARG—atherosclerosis	1.74e-06	1.55e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—atherosclerosis	1.72e-06	1.53e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOE—atherosclerosis	1.71e-06	1.52e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—INS—atherosclerosis	1.71e-06	1.52e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CAV1—atherosclerosis	1.7e-06	1.5e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOA1—atherosclerosis	1.69e-06	1.5e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NOS3—atherosclerosis	1.65e-06	1.46e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—atherosclerosis	1.57e-06	1.39e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CG—atherosclerosis	1.54e-06	1.37e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—atherosclerosis	1.51e-06	1.34e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NOS3—atherosclerosis	1.5e-06	1.33e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARG—atherosclerosis	1.49e-06	1.32e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—INS—atherosclerosis	1.46e-06	1.3e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—atherosclerosis	1.37e-06	1.22e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—atherosclerosis	1.35e-06	1.2e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—atherosclerosis	1.34e-06	1.19e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—atherosclerosis	1.31e-06	1.16e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NOS3—atherosclerosis	1.28e-06	1.14e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—atherosclerosis	1.24e-06	1.1e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—atherosclerosis	1.17e-06	1.04e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—atherosclerosis	1.04e-06	9.24e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—atherosclerosis	9.81e-07	8.7e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—atherosclerosis	9.79e-07	8.68e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—atherosclerosis	9.24e-07	8.2e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKT1—atherosclerosis	7.57e-07	6.71e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—atherosclerosis	6.9e-07	6.12e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—atherosclerosis	5.89e-07	5.23e-06	CbGpPWpGaD
